Reckamp Karen L, Strieter Robert M, Figlin Robert A
Divisions of Medical Oncology and Therapeutics Research & Hematology, City of Hope and Beckman Research Institute, 1500 E Duarte Road, MOB 1001, Duarte, CA 91010, USA.
Expert Rev Anticancer Ther. 2008 Jun;8(6):887-93. doi: 10.1586/14737140.8.6.887.
Targeting novel pathways associated with tumor angiogenesis, invasion and immunity, may lead to improvement in patient outcomes for renal cell carcinoma. Chemokines potentiate tumor growth, metastasis, angiogenesis and immune evasion through interactions with stromal cells and neoplastic cells. Further understanding of the mechanisms involved in chemokine-mediated angiogenesis and metastasis may lead to improved therapeutic strategies in this disease. Interactions between chemokine expression and signaling, and the VEGF and hypoxia-inducible factor pathways offer important opportunities to intervene in the process of renal cell carcinoma proliferation, angiogenesis and invasion. Modulation of the CXCR3/CXCR3-ligand or the CXCR4/CXCL12 biologic axis may be potential therapeutic targets for the treatment of renal cell carcinoma. Furthermore, combination treatment with agents targeting chemokine signaling with therapies directed at angiogenesis and tumor immunity may lead to improved outcomes in this disease.
针对与肿瘤血管生成、侵袭和免疫相关的新途径，可能会改善肾细胞癌患者的预后。趋化因子通过与基质细胞和肿瘤细胞相互作用，增强肿瘤生长、转移、血管生成和免疫逃逸。进一步了解趋化因子介导的血管生成和转移所涉及的机制，可能会改善该疾病的治疗策略。趋化因子表达与信号传导之间的相互作用，以及血管内皮生长因子（VEGF）和缺氧诱导因子途径，为干预肾细胞癌增殖、血管生成和侵袭过程提供了重要机会。调节CXCR3/CXCR3配体或CXCR4/CXCL12生物学轴可能是治疗肾细胞癌的潜在治疗靶点。此外，将针对趋化因子信号传导的药物与针对血管生成和肿瘤免疫的疗法联合使用，可能会改善该疾病的治疗效果。
